Novartis Prexige NDA Has Data Vs. COX-2s; Forest Filing Lexapro Extensions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis’ NDA for its COX-2 inhibitor Prexige, contains clinical studies in osteoarthritis, rheumatoid arthritis, acute pain (including postoperative and dental) and primary dysmenorrhea.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class